Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents
Open Access
- 30 July 2013
- journal article
- Published by Springer Nature in Clinical Epigenetics
- Vol. 5 (1) , 12
Abstract
Several new therapeutic strategies are now considered for acute myeloid leukemia (AML) patients unfit for intensive chemotherapy, including modulation of protein lysine acetylation through inhibition of histone deacetylases (HDACs). These enzymes alter the acetylation of several proteins, including histones and transcription factors, as well as several other proteins directly involved in the regulation of cell proliferation, differentiation and apoptosis. Valproic acid (VPA) is a HDAC inhibitor that has been investigated in several clinical AML studies, usually in combination with all-trans retinoic acid (ATRA) for treatment of patients unfit for intensive chemotherapy, for example older patients, and many of these patients have relapsed or primary resistant leukemia. The toxicity of VPA in these patients is low and complete hematological remission lasting for several months has been reported for a few patients (<5% of included patients), but increased peripheral blood platelet counts are seen for 30 to 40% of patients and may last for up to 1 to 2 years. We review the biological effects of VPA on human AML cells, the results from clinical studies of VPA in the treatment of AML and the evidence for combining VPA with new targeted therapy. However, it should be emphasized that VPA has not been investigated in randomized clinical studies. Despite this lack of randomized studies, we conclude that disease-stabilizing treatment including VPA should be considered especially in unfit patients, because the possibility of improving normal blood values has been documented in several studies and the risk of clinically relevant toxicity is minimal.Keywords
This publication has 132 references indexed in Scilit:
- Inhibition of Mammalian Target of Rapamycin in Human Acute Myeloid Leukemia Cells Has Diverse Effects That Depend on the Environmental In Vitro StressBone Marrow Research, 2012
- Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategiesClinical Epigenetics, 2011
- Specific cellular signal-transduction responses to in vivo combination therapy with ATRA, valproic acid and theophylline in acute myeloid leukemiaBlood Cancer Journal, 2011
- Molecular marks for epigenetic identification of developmental and cancer stem cellsClinical Epigenetics, 2010
- Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapyClinical Epigenetics, 2010
- Histone deacetylase inhibitors: clinical implications for hematological malignanciesClinical Epigenetics, 2010
- Combination of Intensive Chemotherapy and Anticancer Vaccines in the Treatment of Human Malignancies: The Hematological ExperienceJournal of Biomedicine and Biotechnology, 2010
- Significance of heat-shock protein (HSP) 90 expression in acute myeloid leukemia cellsCell Stress and Chaperones, 2008
- The Epigenomics of CancerCell, 2007
- Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemiaBlood, 2006